Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibecotamab vedotin + Pucotenlimab in locally advanced nasopharyngeal carcinoma (phase 2, single-arm)
ChiCTR2600123143Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and pucotenlimab in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Complete response rate (CR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600123143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123143.